Different cell cycle modulation by celecoxib at different concentrations

Cancer Biotherapy and Radiopharmaceuticals

Volumn 28, Issue 2, 2013, Pages 138-145

  Kim, Young Mee ^a   Pyo, Hongryull ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

celecoxib; cell cycle; cyclooxygenase 2; Radiation

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROTEIN P21;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; M PHASE CELL CYCLE CHECKPOINT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; GAMMA RAYS; HUMANS; LUNG NEOPLASMS; PYRAZOLES; RNA, SMALL INTERFERING; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84874724883     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2012.1264     Document Type: Article

References (26)

1. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annu Rev Biochem 1991; 60:281.
2. Williams CS, Shattuck-Brandt RL, DuBois RN. The role of COX-2 in intestinal cancer. Expert Opin Investig Drugs 1999;8:1.
3. Maier TJ, Schilling K, Schmidt R, et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67:1469.
4. Kim YM, Pyo H. Cooperative enhancement of radiosensitivity after combined treatment of 17-(allylamino)-17- demethoxygeldanamycin and celecoxib in human lung and colon cancer cell lines. DNA Cell Biol 2011;31:15.
5. Pyo H, Dubois RN, Hak C. The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapy. In: Choy H (ed.). Chemoradiation in Cancer Therapy. New Jersey: Human Press, 2003;391.
6. Han C, Leng J, Demetris AJ, et al. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: Evidence for cyclooxygenase-2-independent mechanism in celecoxibmediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 2004;64:1369.
7. Hung WC, Chang HC, Pan MR, et al. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol Pharmacol 2000;58: 1398.
8. Toyoshima T, Kamijo R, Takizawa K, et al. Inhibitor of cyclooxygenase- 2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 2002;86:1150.
9. Cheng J, Imanishi H, Amuro Y, et al. NS-398, a selective cyclooxygenase 2 inhibitor, inhibited cell growth and induced cell cycle arrest in human hepatocellular carcinoma cell lines. Int J Cancer 2002;99:755.
10. Narayanan BA, Condon MS, Bosland MC, et al. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: Effects on cyclooxygenase- 2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003;9:3503.
11. Yamashita H, Osaki M, Honjo S, et al. A selective cyclooxygenase- 2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 2003;23:4671.
12. Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase- 2 enzyme: Mechanistic considerations. Int J Radiat Oncol Biol Phys 2002;54:886.
13. Kase S, Osaki M, Honjo S, et al. A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/M phase in human esophageal squamous cell carcinoma cells. J Exp Clin Cancer Res 2004;23:301.
14. Lanza-Jacoby S, Dicker AP, Miller S, et al. Cyclooxygenase (COX)-2-dependent effects of the inhibitor SC236 when combined with ionizing radiation in mammary tumor cells derived from HER-2/neu mice. Mol Cancer Ther 2004;3:417.
15. Shin YK, Park JS, Kim HS, et al. Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 2005;65:9501.
16. Kang HK, Lee E, Pyo H, et al. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005;4:1358.
17. Kim YM, Lee YM, Park SY et al. Ataxia telangiectasia and Rad3-related overexpressing cancer cells induce prolonged G arrest and develop resistance to ionizing radiation. DNA Cell Biol 2011;30:219.
18. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 2000;12:658.
19. Wilson GD. Radiation and the cell cycle, revisited. Cancer Metastasis Rev 2004;23:209.
20. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J RadiatOncol Biol Phys 2004;59:928.
21. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803.
22. Pines J. Mitosis: A matter of getting rid of the right protein at the right time. Trends Cell Biol 2006;16:55.
23. Tenzer A, Pruschy M. Potentiation of DNA-damage-induced cytotoxicity by G2 checkpoint abrogators. Curr Med Chem Anticancer Agents 2003;3:35.
24. Anderson HJ, Andersen RJ, Roberge M. Inhibitors of the G2 DNA damage checkpoint and their potential for cancer therapy. Prog Cell Cycle Res 2003;5:423.
25. Patel MI, Subbaramaiah K, Du B, et al. Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 2005;11:1999.
26. Davies NM, McLachlan AJ, Day RO, et al. Clinical pharmacokinetics and pharmacodynamics of celecoxib: A selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225.